Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.

Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). For imaging, patients received between 230 and 520 micrograms of 131I labelled antibody. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Ford, C. H., Newman, C. E., Johnson, J. R., Woodhouse, C. S., Reeder, T. A., Rowland, G. F., Simmonds, R. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1983
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011264/
https://www.ncbi.nlm.nih.gov/pubmed/6821632
_version_ 1782136494915321856
author Ford, C. H.
Newman, C. E.
Johnson, J. R.
Woodhouse, C. S.
Reeder, T. A.
Rowland, G. F.
Simmonds, R. G.
author_facet Ford, C. H.
Newman, C. E.
Johnson, J. R.
Woodhouse, C. S.
Reeder, T. A.
Rowland, G. F.
Simmonds, R. G.
author_sort Ford, C. H.
collection PubMed
description Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). For imaging, patients received between 230 and 520 micrograms of 131I labelled antibody. In 5, localisation of conjugate was demonstrated, in another it was equivocal and in 2 patients, undetectable. For assessment of safety each patient also received a single dose of conjugate increasing from 1.2 to 42 mg antibody linked to 24 to 1800 micrograms VDS. The in vitro activity of the anti-CEA antibody and its ability to localise in vivo were preserved after conjugation. There was no obvious toxicity or hypersensitivity attributable to either the radiolocalisation or escalated doses of conjugate in any of the patients. The feasibility of the preparation and administration to patients of a vindesine-antibody conjugate has been demonstrated. IMAGES:
format Text
id pubmed-2011264
institution National Center for Biotechnology Information
language English
publishDate 1983
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20112642009-09-10 Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Ford, C. H. Newman, C. E. Johnson, J. R. Woodhouse, C. S. Reeder, T. A. Rowland, G. F. Simmonds, R. G. Br J Cancer Research Article Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). For imaging, patients received between 230 and 520 micrograms of 131I labelled antibody. In 5, localisation of conjugate was demonstrated, in another it was equivocal and in 2 patients, undetectable. For assessment of safety each patient also received a single dose of conjugate increasing from 1.2 to 42 mg antibody linked to 24 to 1800 micrograms VDS. The in vitro activity of the anti-CEA antibody and its ability to localise in vivo were preserved after conjugation. There was no obvious toxicity or hypersensitivity attributable to either the radiolocalisation or escalated doses of conjugate in any of the patients. The feasibility of the preparation and administration to patients of a vindesine-antibody conjugate has been demonstrated. IMAGES: Nature Publishing Group 1983-01 /pmc/articles/PMC2011264/ /pubmed/6821632 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ford, C. H.
Newman, C. E.
Johnson, J. R.
Woodhouse, C. S.
Reeder, T. A.
Rowland, G. F.
Simmonds, R. G.
Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
title Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
title_full Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
title_fullStr Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
title_full_unstemmed Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
title_short Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.
title_sort localisation and toxicity study of a vindesine-anti-cea conjugate in patients with advanced cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011264/
https://www.ncbi.nlm.nih.gov/pubmed/6821632
work_keys_str_mv AT fordch localisationandtoxicitystudyofavindesineanticeaconjugateinpatientswithadvancedcancer
AT newmance localisationandtoxicitystudyofavindesineanticeaconjugateinpatientswithadvancedcancer
AT johnsonjr localisationandtoxicitystudyofavindesineanticeaconjugateinpatientswithadvancedcancer
AT woodhousecs localisationandtoxicitystudyofavindesineanticeaconjugateinpatientswithadvancedcancer
AT reederta localisationandtoxicitystudyofavindesineanticeaconjugateinpatientswithadvancedcancer
AT rowlandgf localisationandtoxicitystudyofavindesineanticeaconjugateinpatientswithadvancedcancer
AT simmondsrg localisationandtoxicitystudyofavindesineanticeaconjugateinpatientswithadvancedcancer

Ejemplares similares